Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.
Schmid S, Holer L, Gysel K, Koster KL, Rothschild SI, Boos LA, Frehner L, Cardoso Almeida S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur WD, Allemann A, Waibel C, Von der Mühll-Schill C, Früh M, Mauti LA.
Schmid S, et al. Among authors: mark m.
JTO Clin Res Rep. 2024 Oct 15;5(12):100735. doi: 10.1016/j.jtocrr.2024.100735. eCollection 2024 Dec.
JTO Clin Res Rep. 2024.
PMID: 39624250
Free PMC article.